Beyond Revlimid: Celgene's 2015 Plan Targets New Business Areas

Celgene is on a course to transition from a company centered mainly on the multiple myeloma blockbuster Revlimid to a diversified biotech over the next five years. That's the strategy management laid out for investors during an R&D day in New York April 8